Biogen and Bio-Thera Report Progress On Tocilizumab
Firms Reveal Positive Phase III Data For Actemra/RoActemra Rival
Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.
You may also be interested in...
Bio-Thera Solutions has claimed the first approval for a biosimilar rival to Actemra/RoActemra anywhere in the world, after receiving a nod from China’s NMPA for its BAT1806 tocilizumab candidate.
China’s Bio-Thera Solutions has revealed the details of its latest clinical trials for proposed biosimilar rivals to Cosentyx (secukinumab) and Nucala (mepolizumab).
Biogen is looking for its ranibizumab biosimilar Byooviz to make a splash in 2023 as it continues to forecast falling biosimilars sales for 2022.